<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12994">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02937766</url>
  </required_header>
  <id_info>
    <org_study_id>AMAG-HPC-HPM-301</org_study_id>
    <nct_id>NCT02937766</nct_id>
  </id_info>
  <brief_title>Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women</brief_title>
  <official_title>A Phase III, Single-Center, Open-labeled, Randomized Controlled Study Assessing Injection Pain of Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AMAG Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AMAG Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) delivered
      subcutaneously via auto-injector is associated with less pain as compared to intramuscular
      injections of Makena®
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of average pain intensity</measure>
    <time_frame>4 weeks</time_frame>
    <description>Comparison of average pain intensity associated with the administration of Makena® via subcutaneous auto-injector versus intramuscular injection (averaged over 4 visits). Pain will be assessed using a numerical pain rating scale (NPRS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigate the clinician's assessment of the ease of drug preparation and ease of injection technique</measure>
    <time_frame>4 weeks</time_frame>
    <description>Investigate the clinician's assessment of the ease of drug preparation and ease of injection technique associated with the administration of Makena® via subcutaneous auto-injector versus intramuscular injection as measured by a categorical scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigate the average pain intensity</measure>
    <time_frame>4 weeks</time_frame>
    <description>Investigate the average pain intensity associated with the administration of Makena® via subcutaneous auto-injector versus intramuscular injection over the 24 hours post injection (averaged over 4 visits) as measured by NPRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigate the worst pain intensity</measure>
    <time_frame>4 weeks</time_frame>
    <description>Investigate the worst pain intensity associated with the administration of Makena® via subcutaneous auto-injector versus intramuscular injection (averaged over 4 visits) as measured by NPRS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous (SQ) injection using an autoinjector weekly over 4 weeks (4 injections)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intramuscular injection (IM) using syringe and needle weekly over 4 weeks (4 injections)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <other_name>Makena SQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</intervention_name>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Makena</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female subjects aged 50 to 75 years of age, inclusive, at Screening Visit.

          2. FSH levels greater than 40 mIU/mL.

          3. Naturally or surgically postmenopausal with or without an intact uterus.

        Exclusion Criteria:

          1. Have history of or positive test results for HIV or hepatitis B or C.

          2. A significant history or current evidence of chronic infectious disease, organ
             dysfunction especially cardiovascular, renal, or hepatic disorders or other medical
             condition.

          3. Receiving or have received chronic opioid therapy within 12 months.

          4. Unwilling to stop taking/using:

               -  pain medication.

               -  topical analgesic or anti-inflammatory treatment. Topical analgesics must be
                  washed out by at least 72 hours in the areas to be treated before randomization.

          5. History of alcohol abuse (regularly drinks &gt; 4 units of alcohol per day; 8 oz. beer,
             3 oz. wine, 1 oz. spirits) or prescription/illicit drug abuse in the last 12 months.

          6. Currently taking any estrogen/progesterone hormone replacement therapy (HRT).

          7. History of allergy or sensitivity to hydroxyprogesterone caproate, castor oil or any
             of the constituents of the study medications or history of any drug hypersensitivity
             or intolerance.

          8. Poorly controlled diabetes (Hgb A1C &gt;8).

          9. Current or history of thrombosis or thromboembolic disorders.

         10. Known or suspected breast cancer, other hormone-sensitive cancer or tumor, or history
             of these conditions within the last 5 years.

         11. Any current or recent (within previous 12 months) vaginal bleeding.

         12. Uncontrolled hypertension.

         13. A chronic pain condition (i.e. chronic back pain) that may confound the assessments
             of injection pain.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Singla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lotus Clinical Research, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lotus Clinical Research, LLC</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 11, 2017</lastchanged_date>
  <firstreceived_date>October 17, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>17-alpha-hydroxy-progesterone caproate</mesh_term>
    <mesh_term>11-hydroxyprogesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
